• Je něco špatně v tomto záznamu ?

Emerging microtubule targets in glioma therapy

CD. Katsetos, MJ. Reginato, PW. Baas, L. D'Agostino, A. Legido, JA. Tuszyn Ski, E. Dráberová, P. Dráber,

. 2015 ; 22 (1) : 49-72. [pub] 20150404

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010193

Grantová podpora
NT14467 MZ0 CEP - Centrální evidence projektů

Major advances in the genomics and epigenomics of diffuse gliomas and glioblastoma to date have not been translated into effective therapy, necessitating pursuit of alternative treatment approaches for these therapeutically challenging tumors. Current knowledge of microtubules in cancer and the development of new microtubule-based treatment strategies for high-grade gliomas are the topic in this review article. Discussed are cellular, molecular, and pharmacologic aspects of the microtubule cytoskeleton underlying mitosis and interactions with other cellular partners involved in cell cycle progression, directional cell migration, and tumor invasion. Special focus is placed on (1) the aberrant overexpression of βIII-tubulin, a survival factor associated with hypoxic tumor microenvironment and dynamic instability of microtubules; (2) the ectopic overexpression of γ-tubulin, which in addition to its conventional role as a microtubule-nucleating protein has recently emerged as a transcription factor interacting with oncogenes and kinases; (3) the microtubule-severing ATPase spastin and its emerging role in cell motility of glioblastoma cells; and (4) the modulating role of posttranslational modifications of tubulin in the context of interaction of microtubules with motor proteins. Specific antineoplastic strategies discussed include downregulation of targeted molecules aimed at achieving a sensitization effect on currently used mainstay therapies. The potential role of new classes of tubulin-binding agents and ATPase inhibitors is also examined. Understanding the cellular and molecular mechanisms underpinning the distinct behaviors of microtubules in glioma tumorigenesis and drug resistance is key to the discovery of novel molecular targets that will fundamentally change the prognostic outlook of patients with diffuse high-grade gliomas.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010193
003      
CZ-PrNML
005      
20191022094257.0
007      
ta
008      
160408s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.spen.2015.03.009 $2 doi
024    7_
$a 10.1016/j.spen.2015.03.009 $2 doi
035    __
$a (PubMed)25976261
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Katsetos, Christos D $u Department of Pediatrics, Drexel University College of Medicine, Section of Neurology and Pediatric Neuro-oncology Program, St Christopher's Hospital for Children, Philadelphia, PA; Department of Pathology and Laboratory Medicine, Drexel University College of Medicine, Philadelphia, PA. Electronic address: Christos.Katsetos@drexelmed.edu.
245    10
$a Emerging microtubule targets in glioma therapy / $c CD. Katsetos, MJ. Reginato, PW. Baas, L. D'Agostino, A. Legido, JA. Tuszyn Ski, E. Dráberová, P. Dráber,
520    9_
$a Major advances in the genomics and epigenomics of diffuse gliomas and glioblastoma to date have not been translated into effective therapy, necessitating pursuit of alternative treatment approaches for these therapeutically challenging tumors. Current knowledge of microtubules in cancer and the development of new microtubule-based treatment strategies for high-grade gliomas are the topic in this review article. Discussed are cellular, molecular, and pharmacologic aspects of the microtubule cytoskeleton underlying mitosis and interactions with other cellular partners involved in cell cycle progression, directional cell migration, and tumor invasion. Special focus is placed on (1) the aberrant overexpression of βIII-tubulin, a survival factor associated with hypoxic tumor microenvironment and dynamic instability of microtubules; (2) the ectopic overexpression of γ-tubulin, which in addition to its conventional role as a microtubule-nucleating protein has recently emerged as a transcription factor interacting with oncogenes and kinases; (3) the microtubule-severing ATPase spastin and its emerging role in cell motility of glioblastoma cells; and (4) the modulating role of posttranslational modifications of tubulin in the context of interaction of microtubules with motor proteins. Specific antineoplastic strategies discussed include downregulation of targeted molecules aimed at achieving a sensitization effect on currently used mainstay therapies. The potential role of new classes of tubulin-binding agents and ATPase inhibitors is also examined. Understanding the cellular and molecular mechanisms underpinning the distinct behaviors of microtubules in glioma tumorigenesis and drug resistance is key to the discovery of novel molecular targets that will fundamentally change the prognostic outlook of patients with diffuse high-grade gliomas.
650    _2
$a zvířata $7 D000818
650    _2
$a antitumorózní látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a karcinogeneze $x účinky léků $x genetika $x metabolismus $7 D063646
650    _2
$a regulace genové exprese u nádorů $x účinky léků $x genetika $7 D015972
650    _2
$a gliom $x farmakoterapie $x genetika $x metabolismus $7 D005910
650    _2
$a lidé $7 D006801
650    _2
$a mikrotubuly $x účinky léků $x genetika $x metabolismus $7 D008870
650    _2
$a neuronové sítě (počítačové) $7 D016571
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Reginato, Mauricio J $u Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA.
700    1_
$a Baas, Peter W $u Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, PA.
700    1_
$a D'Agostino, Luca $u Department of Pediatrics, Drexel University College of Medicine, Section of Neurology and Pediatric Neuro-oncology Program, St Christopher's Hospital for Children, Philadelphia, PA.
700    1_
$a Legido, Agustin $u Department of Pediatrics, Drexel University College of Medicine, Section of Neurology and Pediatric Neuro-oncology Program, St Christopher's Hospital for Children, Philadelphia, PA.
700    1_
$a Tuszyn Ski, Jack A $u Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada; Department of Physics, University of Alberta, Edmonton, Alberta, Canada.
700    1_
$a Dráberová, Eduarda $u Department of Biology of Cytoskeleton, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic. $7 xx0065234
700    1_
$a Dráber, Pavel $u Department of Biology of Cytoskeleton, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic. $7 xx0065228
773    0_
$w MED00004937 $t Seminars in pediatric neurology $x 1558-0776 $g Roč. 22, č. 1 (2015), s. 49-72
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25976261 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20191022094731 $b ABA008
999    __
$a ok $b bmc $g 1113622 $s 934561
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 22 $c 1 $d 49-72 $e 20150404 $i 1558-0776 $m Seminars in pediatric neurology $n Semin Pediatr Neurol $x MED00004937
GRA    __
$a NT14467 $p MZ0
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Možnosti archivace